{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:11:37Z","timestamp":1778803897311,"version":"3.51.4"},"reference-count":37,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.clml.2024.10.006","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T16:08:15Z","timestamp":1728490095000},"page":"e1-e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["A Real-World Analysis on Access to Triplet and Quadruplet Therapy in Newly Diagnosed Multiple Myeloma Patients in the United States"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2743-674X","authenticated-orcid":false,"given":"Ludovic","family":"Saba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chieh-Lin","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9148-8894","authenticated-orcid":false,"given":"Hong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4641-2217","authenticated-orcid":false,"given":"Chakra P.","family":"Chaulagain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2024.10.006_bib0001","unstructured":"Cancer statistics, 2022, Siegel - 2022 - CA: A cancer journal for clinicians - Wiley online library. [Accessed: Jul 19 2023]. Available at: https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.3322\/caac.21708."},{"key":"10.1016\/j.clml.2024.10.006_bib0002","unstructured":"Association of response endpoints with survival outcomes in multiple myeloma - PubMed. [Accessed Jul 19 2023]. Available at: https:\/\/pubmed.ncbi.nlm.nih.gov\/23868105\/."},{"key":"10.1016\/j.clml.2024.10.006_bib0003","first-page":"1","article-title":"The survival time of patients with plasmocytic myeloma","volume":"9","author":"Osgood","year":"1960","journal-title":"Cancer Chemother Rep"},{"issue":"5","key":"10.1016\/j.clml.2024.10.006_bib0004","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41408-020-0311-8","volume":"10","author":"Durie","year":"2020","journal-title":"Blood Cancer J"},{"issue":"11","key":"10.1016\/j.clml.2024.10.006_bib0005","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomized, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.clml.2024.10.006_bib0006","doi-asserted-by":"crossref","first-page":"e874","DOI":"10.1016\/S2352-3026(20)30356-2","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomized, open-label, phase 3 trial","volume":"7","author":"Roussel","year":"2020","journal-title":"Lancet Haematol"},{"issue":"8","key":"10.1016\/j.clml.2024.10.006_bib0007","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2024.10.006_bib0008","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.clml.2024.10.006_bib0009","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1056\/NEJMe1609835","article-title":"Progress in myeloma - a monoclonal breakthrough","volume":"375","author":"Rajkumar","year":"2016","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.clml.2024.10.006_bib0010","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","article-title":"Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016","volume":"4","author":"Cowan","year":"2018","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.clml.2024.10.006_bib0011","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.clml.2018.08.005","article-title":"Analysis of availability and access of anti-myeloma drugs and impact on the management of multiple myeloma in Latin American countries","volume":"19","author":"Pessoa de Magalh\u00e3es Filho","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"10.1016\/j.clml.2024.10.006_bib0012","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1002\/cncr.31305","article-title":"Impact of the affordability of novel agents in patients with multiple myeloma: Real-world data of current clinical practice in Mexico","volume":"124","author":"Tar\u00edn-Arzaga","year":"2018","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.clml.2024.10.006_bib0013","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1002\/cam4.1347","article-title":"Epidemiology of multiple myeloma in 17 Latin American countries: an update","volume":"7","author":"Curado","year":"2018","journal-title":"Cancer Med"},{"issue":"20","key":"10.1016\/j.clml.2024.10.006_bib0014","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1182\/bloodadvances.2019000308","article-title":"Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis","volume":"3","author":"Ailawadhi","year":"2019","journal-title":"Blood Adv"},{"issue":"24","key":"10.1016\/j.clml.2024.10.006_bib0015","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1182\/blood.2019000406","article-title":"With equal access, African American patients have superior survival compared to white patients with multiple myeloma: a VA study","volume":"133","author":"Fillmore","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2024.10.006_bib0016","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA: Cancer J Clin"},{"issue":"11","key":"10.1016\/j.clml.2024.10.006_bib0017","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clml.2024.10.006_bib0018","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.clml.2024.10.006_bib0019","doi-asserted-by":"crossref","first-page":"4538","DOI":"10.1182\/bloodadvances.2020002393","article-title":"Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma","volume":"4","author":"Pillarisetti","year":"2020","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.clml.2024.10.006_bib0020","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clml.2024.10.006_bib0021","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41408-020-0284-7","article-title":"Dissecting racial disparities in multiple myeloma","volume":"10","author":"Marinac","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2024.10.006_bib0022","unstructured":"USCS Data Visualizations. [Accessed 2023 Aug 8]. Available at: https:\/\/gis.cdc.gov\/grasp\/USCS\/DataViz.html."},{"issue":"4","key":"10.1016\/j.clml.2024.10.006_bib0023","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1188\/20.CJON.439-443","article-title":"African American patients with multiple myeloma: optimizing care to decrease racial disparities","volume":"24","author":"Pierre","year":"2020","journal-title":"Clin J Oncol Nurs"},{"issue":"2","key":"10.1016\/j.clml.2024.10.006_bib0024","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41408-022-00633-5","article-title":"Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study","volume":"12","author":"Dong","year":"2022","journal-title":"Blood Cancer J"},{"issue":"15","key":"10.1016\/j.clml.2024.10.006_bib0025","doi-asserted-by":"crossref","first-page":"8022","DOI":"10.1200\/JCO.2016.34.15_suppl.8022","article-title":"Disparities in treatment patterns and outcomes between Caucasian and African American patients with multiple myeloma (MM)","volume":"34","author":"Abouzaid","year":"2016","journal-title":"JCO"},{"issue":"2","key":"10.1016\/j.clml.2024.10.006_bib0026","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-019-0177-9","article-title":"Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients","volume":"9","author":"Kazandjian","year":"2019","journal-title":"Blood Cancer J"},{"issue":"18","key":"10.1016\/j.clml.2024.10.006_bib0027","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1182\/bloodadvances.2020004001","article-title":"Lack of differential impact of del17p on survival in African Americans compared with White patients with multiple myeloma: a VA study","volume":"5","author":"Fillmore","year":"2021","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.clml.2024.10.006_bib0028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-019-0254-0","article-title":"Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone","volume":"9","author":"Schmidt","year":"2019","journal-title":"Blood Cancer J"},{"issue":"8","key":"10.1016\/j.clml.2024.10.006_bib0029","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41408-020-00347-6","article-title":"Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis","volume":"10","author":"Derman","year":"2020","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.clml.2024.10.006_bib0030","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s44228-022-00026-2","article-title":"Health disparities experienced by Hispanic Americans with multiple myeloma: a systematic review","volume":"5","author":"Anampa-Guzm\u00e1n","year":"2022","journal-title":"Clin Hematol Int"},{"issue":"11","key":"10.1016\/j.clml.2024.10.006_bib0031","doi-asserted-by":"crossref","first-page":"e420","DOI":"10.1016\/j.clml.2023.08.008","article-title":"Disparities in multiple myeloma treatment patterns in the United States: a systematic review","volume":"23","author":"Gasoyan","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2024.10.006_bib0032","unstructured":"Hospital Volume and 30-Day Mortality for Three Common Medical Conditions | NEJM [Internet]. [Accessed 2023 Aug 30]. Available at: https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMsa0907130."},{"issue":"9","key":"10.1016\/j.clml.2024.10.006_bib0033","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0108754","article-title":"The effect of hospital volume on mortality in patients admitted with severe sepsis","volume":"9","author":"Shahul","year":"2014","journal-title":"PLoS One"},{"issue":"22","key":"10.1016\/j.clml.2024.10.006_bib0034","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1200\/JCO.2017.72.3742","article-title":"Rising prices of targeted oral anticancer medications and associated financial burden on medicare beneficiaries","volume":"35","author":"Shih","year":"2017","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clml.2024.10.006_bib0035","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1002\/cam4.1246","article-title":"Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER-medicare analysis","volume":"6","author":"Ailawadhi","year":"2017","journal-title":"Cancer Med."},{"key":"10.1016\/j.clml.2024.10.006_bib0036","unstructured":"More evidence on the limited impact of state oral oncology parity laws - PubMed [Internet]. [Accessed 2023 Sep 15]. Available at: https:\/\/pubmed.ncbi.nlm.nih.gov\/30566761\/."},{"key":"10.1016\/j.clml.2024.10.006_bib0037","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1200\/EDBK_200867","article-title":"Value and cost of myeloma therapy","volume":"38","author":"Rajkumar","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024023620?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024023620?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T06:39:23Z","timestamp":1736059163000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024023620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S2152265024023620"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.10.006","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Real-World Analysis on Access to Triplet and Quadruplet Therapy in Newly Diagnosed Multiple Myeloma Patients in the United States","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}